The progression of HCC in the era of DAA therapy is critical in determining the onset or recurrence of cancer after HCV eradication. DAAs have shown satisfactory efficacy in the treatment of HCV-sustained viral response (SVR). However, data on HCC risk following DAA-SVR remains contradictory. The purpose of this study is to look at HCC onset in people who have the moderate underlying liver disease by detecting levels of IDO enzyme that show a massive increase in HCC patients compared to recently diagnosed patients with HCV infection and cirrhosis-related HCV patients.² These findings raise the possibility that in considering IDO, more than an enzyme, as a marker predicting the development of HCC after HCV eradication. It's also possible that DAA therapy may be the cause of rising IDO levels, which requires further investigation.so we conducted this work aiming to compare the level of IDO enzyme with the progression of HCC despite curing with DAA therapy and studying the effect of therapy on patients by analyzing the severity and predicting suitable biomarkers for detecting HCC occurrence in cured patients from HCV infection by DAA that progress HCC.